Amneal, Lupin to Pay $3.4 Million in Antitrust Deal Over Xyrem

A $3.4 million antitrust settlement between a class of plaintiffs and drugmakers Amneal Pharmaceuticals Inc. and Lupin Ltd. over claims they delayed the generic version of narcolepsy drug Xyrem got a federal judge’s final approval.

Judge Richard Seeborg of the US District Court for the Northern District of California in a Wednesday order called the deal “fair, reasonable, and adequate” for settlement class members including insurers and beneficiaries who paid or reimbursed some or all of the purchase price for Xyrem or Xywav, a similar drug, starting from Jan. 1, 2015. Seeborg granted preliminary approval of the deal roughly a ...